Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Poseida Therapeutics Q2 EPS $(0.32) Beats $(0.41) Estimate, Sales $25.97M Beat $15.43M Estimate

Author: Benzinga Newsdesk | August 05, 2024 04:39pm
Poseida Therapeutics (NASDAQ:PSTX) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.41) by 21.95 percent. This is unchanged from the same period last year. The company reported quarterly sales of $25.97 million which beat the analyst consensus estimate of $15.43 million by 68.33 percent. This is a 29.78 percent increase over sales of $20.01 million the same period last year.

Posted In: PSTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist